{"id":"W3165865880","doi":"10.1136/annrheumdis-2021-eular.960","title":"AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Pfizer; Eli Lilly and Company","keywords":"Medicine; Psoriasis; Psoriasis Area and Severity Index; Placebo; Internal medicine; Adalimumab; Clinical trial; Clearance; Randomized controlled trial; Surgery; Immunology; Urology; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0004243019,0.0001291433,0.0005928947,0.00001238423,0.00006475136,0.00001014884,0.0002106753,0.0000341345,0.0001573311],"category_scores_gemma":[0.009071942,0.00006834743,0.0003846694,0.0002018085,0.0002998652,0.00007389249,0.0001015742,0.00007459895,0.000005379529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001275515,"about_ca_system_score_gemma":0.000181281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004949428,"about_ca_topic_score_gemma":0.00001236645,"domain_scores_codex":[0.9981299,0.0005016678,0.0006473981,0.0001770788,0.0003606337,0.0001833301],"domain_scores_gemma":[0.9932824,0.005219273,0.0005689957,0.000659221,0.0002021968,0.00006791567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7293183,0.01108001,0.0007839733,0.0004124368,0.006377971,0.000116695,0.009692875,0.00002596077,0.003000083,0.0008712604,0.06489366,0.1734268],"study_design_scores_gemma":[0.3886883,0.009394298,0.1668579,0.008748313,0.008777744,0.00003445311,0.01367771,0.0004028036,0.1239721,0.01177459,0.2669348,0.0007369212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972873,0.009919529,0.000005184198,0.01403234,0.0001791033,0.0004988385,0.001666253,0.00001031158,0.0008154956],"genre_scores_gemma":[0.9914133,0.007241824,0.00007394121,0.0006273271,0.00004737784,0.00001588698,0.00002462745,0.00001123415,0.0005444749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3406299,"threshold_uncertainty_score":0.9992751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1498465969173492,"score_gpt":0.4241457042358771,"score_spread":0.2742991073185279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}